AHRQ updates Horizon Scan on latest health IT innovations

Laura Pedulli | | Health Exec | Economics

The Agency for Healthcare Research and Quality (AHRQ) has published the tenth edition of its Healthcare Horizon Scanning System, an update that includes 35 new technologies and identifies 487 innovations that are being tracked for their potential impact on clinical care, healthcare systems, patient outcomes and costs.

The emerging healthcare technology innovations touch on several areas, including cancer, diabetes mellitus, cardiovascular disease, obesity, and depression and other mental health disorders.

“Identifying emerging healthcare technologies and innovations can help inform patient-centered outcomes research and support planning and prioritization of research resources. Health plans and health system purchasers need this information to plan for the future, as they consider upcoming innovations on the horizon,” according to an AHRQ notice.

The update reflects AHRQ’s December 2013 Potential High Impact Reports, which was developed by the Effective Health Care Program.

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.